Literature DB >> 14618558

A new approach to the qualitative evaluation of functional disability in dementia.

X Kurz1, J Scuvee-Moreau, B Rive, A Dresse.   

Abstract

BACKGROUND: Dementia patients suffer from the progressive deterioration of cognitive and functional abilities. Instrumental disabilities usually appear in the earlier stages of the disease while basic disabilities appear in the more advanced stages. In order to differentiate between mild, moderate and severe patients both instrumental and basic functional disabilities should be taken into account simultaneously.
OBJECTIVES: The objective of this study was to find a new method for classifying dementia patients based on their disabilities by using a basic and an instrumental Activities of Daily Living (ADL) scale.
METHODS: Functional disability was assessed in a Belgian cohort of dementia patients using the Katz and Lawton Instrumental Activities of Daily Living (IADL) scales. A k-means derived clustering method allocated patients to disability clusters according to their Katz and Lawton scores. In order to validate the classification, we compared socio-demographic, clinical and costs parameters between the groups.
RESULTS: The clustering method allocated patients between three clusters: dependent, non-dependent with instrumental functional disability (ND-IFD) and non-dependent. Dependence, as defined by these clusters, significantly correlates with age, residential setting, MMSE, patient's quality of life and costs.
CONCLUSION: This new classification of patients suffering from dementia will provide better understanding of functional disabilities and will complement the evaluation of disease severity based on cognitive function. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2003        PMID: 14618558     DOI: 10.1002/gps.1009

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  9 in total

Review 1.  Dependence as a unifying construct in defining Alzheimer's disease severity.

Authors:  Trent McLaughlin; Howard Feldman; Howard Fillit; Mary Sano; Frederick Schmitt; Paul Aisen; Christopher Leibman; Lisa Mucha; J Michael Ryan; Sean D Sullivan; D Eldon Spackman; Peter J Neumann; Joshua Cohen; Yaakov Stern
Journal:  Alzheimers Dement       Date:  2010-11       Impact factor: 21.566

Review 2.  Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer's Disease.

Authors:  Luis Hernandez; Asli Ozen; Rodrigo DosSantos; Denis Getsios
Journal:  Pharmacoeconomics       Date:  2016-07       Impact factor: 4.981

Review 3.  A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease.

Authors:  Joanna Kirby; Colin Green; Emma Loveman; Andrew Clegg; Joanna Picot; Andrea Takeda; Elizabeth Payne
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 4.  Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.

Authors:  Greg L Plosker; Katherine A Lyseng-Williamson
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective.

Authors:  Roy W Jones; Paul McCrone; Chantal Guilhaume
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

6.  Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease : a markov model in Finland.

Authors:  Clément François; Harri Sintonen; Raimo Sulkava; Benoît Rive
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

7.  Analysis of Risk Factors for Cognitive Dysfunction in Disabled Elderly Patients in Chengdu, China.

Authors:  Xiaoyan Chen; Ying Zhang; Lisha Hou; Yanjiao Shen; Jianqun Li; Birong Dong
Journal:  Med Sci Monit       Date:  2020-07-09

8.  Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia.

Authors:  Christian K Andersen; Kim U Wittrup-Jensen; Anette Lolk; Kjeld Andersen; Per Kragh-Sørensen
Journal:  Health Qual Life Outcomes       Date:  2004-09-21       Impact factor: 3.186

9.  Effects of a Rivastigmine Patch on Self-Care Activities in Patients with Alzheimer's Disease plus Cerebrovascular Disease.

Authors:  Yong Kyun Kim; Kil-Byung Lim; Sang Chul Lee; Jin-Woo Park; Hong-Jae Lee; Bum Sun Kwon; Ho Jun Lee
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2014-10-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.